Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 6Thymulin (Facteur Thymique Serique) literatureLancet (London, England) · ObservationalTop journal1990

Antibodies to thymic hormone and HLA-DQ in type I diabetes.

In type I diabetes patients, antibodies to thymic hormone and HLA-DQ were found in notable proportions, but the clinical implications of these findings are not clear.

Read at Lancet (London, England)Add to compare

Where it sits

this study against the rest of the thymulin (facteur thymique serique) corpus
0
Preclinical
5
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study investigates the presence of antibodies to thymic hormone and HLA-DQ in individuals with type I diabetes. The findings suggest a potential immunological link, though no specific dose or treatment was administered. The relevance of these antibodies in the context of type I diabetes is explored.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=401990

Background

This paper addresses the potential role of thymic hormones and HLA-DQ antibodies in the pathogenesis of type I diabetes. Prior research has indicated that autoimmune responses may contribute to the disease, but the specific involvement of thymic hormones had not been fully elucidated. Understanding these relationships could provide insights into the immunological mechanisms underlying type I diabetes.

Methods

The study involved a population of 40 patients diagnosed with type I diabetes. It assessed the presence of antibodies to thymic hormone and HLA-DQ through serological tests. No specific dosing or treatment protocols were applied, as the focus was on antibody detection rather than intervention.

Results

The study reported that 25% of the type I diabetes patients tested positive for antibodies to thymic hormone, while 60% exhibited HLA-DQ antibodies. However, no p-values or confidence intervals were provided to assess the significance of these findings.

Interpretation

The findings suggest a notable prevalence of HLA-DQ antibodies among type I diabetes patients, which aligns with existing literature on autoimmune markers in this population. However, the effect size is not quantified, and the clinical significance of these antibodies remains uncertain. The small sample size and lack of follow-up data limit the robustness of the conclusions drawn.

Key findings

  • Antibodies to thymic hormone were found in 25% of type I diabetes patients, n=40.
  • HLA-DQ antibodies were present in 60% of patients with type I diabetes, n=40.
  • Not reported in abstract.

Limitations

  • small n=40
  • no follow-up data reported
  • no causative conclusions can be drawn
  • no p-values or confidence intervals provided

Elsewhere in the Thymulin (Facteur Thymique Serique) corpus

AA nonrandomized phase 2 trial of oral thymic peptides in hospitalized patients with Covid-19biorxiv-preprint · 2021 · 0% mortality in thymic peptides group vs 24% mortality in standard care by day 20, log-rank P=0.02.HumanBGrowth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells.The Journal of clinical endocrinology and metabolism · 1992 · Thymulin plasma concentrations in acromegaly patients: 4.24 +/- 0.97 vs. 2.67 +/- 0.87 in controls, P < 0.001.HumanCA Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction.Circulation · 2020 · Not reported in abstract.AnimalBCausal effect between systemic inflammatory cytokines and osteoporotic pathological fractures: A bidirectional Mendelian randomization study.PubMed · 2025 · OR = 0.7954 for Artemin levels negatively correlated with fracture risk, P = .0167.HumanBClinical Significance of B7-H4 in Peripheral Blood of Patients With Myasthenia Gravis.PubMed · 2026 · mB7-H4 expression on CD4+ T cells significantly increased in relapsing-MG patients compared to healthy controls (p < 0.05).Human